am 251 and omdm-2 cpd
am 251 has been researched along with omdm-2 cpd in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Bátkai, S; Bukoski, RD; Harvey-White, J; Kunos, G; Liu, J; Mackie, K; Offertáler, L; Osei-Hyiaman, D; Pacher, P; Radaeva, S; Rudd, MA | 1 |
| Bazan, NG; Boudaba, C; Di, S; Harris, C; Marcheselli, VL; Popescu, IR; Tasker, JG; Weng, FJ | 1 |
Other Studies
2 other study(ies) available for am 251 and omdm-2 cpd
| Article | Year |
|---|---|
Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension.
Topics: Amidohydrolases; Angiotensin II; Animals; Arachidonic Acids; Benzamides; Benzyl Compounds; Blood Pressure; Camphanes; Carbamates; Dronabinol; Endocannabinoids; Endothelium, Vascular; Hypertension; Male; Models, Cardiovascular; Myocardial Contraction; Myocardium; Piperidines; Polyunsaturated Alkamides; Pyrazoles; Rats; Rats, Inbred Dahl; Rats, Inbred SHR; Rats, Inbred WKY; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Up-Regulation; Vascular Resistance; Vasodilation; Ventricular Function, Left | 2004 |
Activity-dependent release and actions of endocannabinoids in the rat hypothalamic supraoptic nucleus.
Topics: Animals; Arachidonic Acids; Benzoxazines; Benzyl Compounds; Cannabinoid Receptor Modulators; Cannabinoids; Endocannabinoids; Excitatory Postsynaptic Potentials; Glutamic Acid; Glycerides; In Vitro Techniques; Male; Morpholines; Naphthalenes; Neurons; Piperidines; Polyunsaturated Alkamides; Presynaptic Terminals; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Receptors, Presynaptic; Supraoptic Nucleus; Synaptic Transmission | 2005 |